#USA #New York #Pomerantz Law Firm #Keros Therapeutics #investigations

Pomerantz Law Firm Investigates Claims Against Keros Therapeutics

Pomerantz LLP, a well-respected law firm specializing in corporate and securities class actions, is currently investigating claims made by investors of Keros Therapeutics, Inc. (NASDAQ: KROS). This scrutiny follows serious allegations that the company and some of its executives may have engaged in fraudulent practices detrimental to shareholders. If you are an affected investor, reaching out to Danielle Peyton at Pomerantz may be crucial as she handles the investigation and can provide necessary guidance.

Background on Keros Therapeutics

Keros Therapeutics is a biopharmaceutical company focused on developing innovative therapies for underserved patient populations with severe diseases. However, the recent events surrounding the company's clinical trials have raised significant alarms.

On December 12, 2024, Keros issued a daunting press release revealing that it was voluntarily halting dosing in part of its Phase 2 clinical trial, TROPOS, related to a drug known as cibotercept (KER-012), which targets pulmonary arterial hypertension (PAH). This action was deemed necessary after a safety review uncovered unanticipated adverse events, specifically instances of pericardial effusion among patients in the trial. The revelation caused Keros's stock to plummet by over 73% in a single day, highlighting the substantial impact that such news can have on investor confidence.

The situation further escalated on January 15, 2025, when the company announced a halt to all dosing in the TROPOS trial. This decision was based on newly observed adverse events and indicated that Keros had informed relevant regulatory authorities, including the FDA, about these developments. As a result of this announcement, the stock faced a further decline of approximately 16%, closing significantly lower than before.

Legal Proceedings and Investor Advocacy

Given the serious nature of these incidents, Pomerantz LLP has opened an investigation to assess whether Keros Therapeutics, along with its officers and directors, have committed securities fraud or violated any business regulations. Investors who have suffered financial losses may have legal grounds for joining a class-action suit against the company.

With a storied history stretching back over 85 years, Pomerantz is renowned for its relentless advocacy on behalf of investors. The firm has successfully secured numerous multimillion-dollar settlements in various cases of security violations and corporate misconduct.

If you believe you have been affected by Keros’s actions and wish to learn more about your rights as an investor, contacting Pomerantz is highly recommended. They provide support for individuals considering participation in class-action lawsuits, ensuring that affected parties have an opportunity to seek justice and recover losses.

Conclusion

The recent turmoil at Keros Therapeutics serves as a reminder of the volatility in the biopharmaceutical sector and the potential ramifications when companies diverge from sound business practices. Investors are urged to remain vigilant and stay informed as legal proceedings evolve. For access to further information or to participate in the ongoing investigation, reach out to the contact provided by Pomerantz.

By prioritizing investor rights and holding corporations accountable, law firms like Pomerantz play a pivotal role in the complex landscape of financial securities and ethical governance.